rs879254269
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM1BP4BS2_Supporting
The NM_000371.4(TTR):c.122G>A(p.Arg41Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000753 in 1,461,786 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. R41R) has been classified as Benign.
Frequency
Consequence
NM_000371.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TTR | NM_000371.4 | c.122G>A | p.Arg41Gln | missense_variant | 2/4 | ENST00000237014.8 | NP_000362.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TTR | ENST00000237014.8 | c.122G>A | p.Arg41Gln | missense_variant | 2/4 | 1 | NM_000371.4 | ENSP00000237014 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251468Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135908
GnomAD4 exome AF: 0.00000753 AC: 11AN: 1461786Hom.: 0 Cov.: 31 AF XY: 0.00000688 AC XY: 5AN XY: 727200
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Amyloidosis, hereditary systemic 1 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | Mar 05, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 01, 2021 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Mar 01, 2016 | The R41Q variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The R41Q variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The R41Q variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. However, this substitution occurs at a position that is not conserved across species and where Q41 is the wild type in several species. Finally, in silico analysis predicts this variant likely does not alter the protein structure/function.Therefore, based on the currently available information, it is unclear whether this variant is pathogenic or rare benign. - |
Carpal tunnel syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | Mar 05, 2018 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 24, 2023 | The p.R41Q variant (also known as c.122G>A), located in coding exon 2 of the TTR gene, results from a G to A substitution at nucleotide position 122. The arginine at codon 41 is replaced by glutamine, an amino acid with highly similar properties. This alteration, which is also known as p.R21Q, has been reported in transthyretin (TTR) amyloidosis cohorts and individuals with hypertrophic cardiomyopathy (HCM); however, clinical details were limited in some cases (Lefaucheur JP et al. Clin Neurophysiol, 2018 Aug;129:1565-1569; Damy T et al. Eur Heart J, 2019 Apr;43:391-400; Dang J et al. Mayo Clin Proc, 2019 Jun;94:961-975; Lopes LR et al. Amyloid, 2019 Dec;26:243-247; Auer-Grumbach M et al. J Clin Med, 2020 Jul;9:[ePub ahead of print]; Bézard M et al. Eur J Heart Fail, 2021 Feb;23:264-274). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at